Table 1 Demographic characteristics of the included 93MS women with 116 pregnancies
Characteristic | Value |
|---|---|
Age (mean, SD), years | 32.74 ± 5.12 |
Disease duration, median (IQR), years | 4.5 (1.93–8.92) |
MS subtype at onset of pregnancy, no. (%) | |
RRMS | 109 (93.96%) |
Progressive, relapsing MS | 7 (6.03%) |
Relapses during 2 years before pregnancya | |
0 | 52 (44.83%) |
1 | 43 (37.07%) |
≥ 2 | 21 (18.10%) |
MS-related disability, no. (%) | |
No disability | 70 (60.34%) |
Some disability but fully ambulatory | 37 (31.89%) |
Some ambulatory impairment | 7 (6.03%) |
Cane required | 1 (0.86%) |
Wheelchair required | 1 (0.86%) |
EDSS score before pregnancy, no. (%) | |
0–0.5 | 56 (48.27%) |
1–1.5 | 39 (33.63%) |
2–2.5 | 14 (12.07%) |
3–3.5 | 5 (4.31%) |
≥ 4 | 2 (1.72%) |
DMT use before pregnancy, no. (%) | |
Never | 18 (15.52%) |
At the time of conception | 23 (19.83%) |
Within 1 year prior | 75 (64.65%) |
Type used within 1 year prior | |
Interferon-beta | 39 (33.62%) |
Dimethyl fumarate | 7 (6.03%) |
Natalizumab | 1 (0.86%) |
Rituximab | 9 (7.76%) |
Ocrelizumab | 4 (3.45%) |
Fingolimod | 13 (11.21%) |
Teriflunomide | 2 (1.72%) |
Comorbidities other than MS | |
Hypertension | 8 (6.89%) |
Diabetes mellitus | 1 (0.86%) |
Othersa | 1 (0.86%) |